Jm. Edelman et al., Oral Montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction - A randomized, double-blind trial, ANN INT MED, 132(2), 2000, pp. 97-104
Citations number
30
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background: Montelukast, an oral, once-daily leukotriene receptor antagonis
t, provides protection against exercise-induced bronchoconstriction.
Objective: To evaluate the effect of 8 weeks of therapy with salmeterol aer
osol or montelukast on exercise-induced bronchoconstriction in adults with
asthma.
Design: 8-week multicenter, randomized, double-blind study.
Setting: 17 asthma treatment centers in the United States.
Patients: 191 adults with asthma who had documented exercise-induced bronch
oconstriction.
Intervention: qualified patients were randomly assigned to double-blind tre
atment with montelukast (10 mg once in the evening) or salmeterol (50 mu g
[2 puffs] twice daily).
Measurements: Changes in pre-exercise and postexercise challenge values; pe
rcentage inhibition in the maximal percentage decrease in FEV,; the area ab
ove the FEV1-time curve; and time to recovery of FEV, at days 1 to 3, week
4, and week 8 of treatment.
Results: By day 3, similar and statistically significant reductions in maxi
mal percentage decrease in FEV, were seen with both therapies. Sustained im
provement occurred in the montelukast group at weeks 4 and 8; at these time
points, the bronchoprotective effect of salmeterol decreased significantly
. At week 8, the percentage inhibition in the maximal percentage decrease i
n FEV, was 57.2% in the montelukast group and 33.0% in the salmeterol group
(P = 0,002), By week 8, 67% of patients receiving montelukast and 46% of p
atients receiving salmeterol had a maximal percentage decrease in FEV, of l
ess than 20%,
Conclusions: The bronchoprotective effect of montelukast was maintained thr
oughout 8 weeks of study. In contrast, significant loss of bronchoprotectio
n at weeks 4 and was seen with salmeterol. Long-term administration of mont
elukast provided consistent inhibition of exercise- induced bronchoconstric
tion at the end of the 8-week dosing interval without tolerance.